couter

ANABAnaptysbio, Inc.

Anaptysbio, Inc. (ANAB) generates revenue through royalty streams tied to its partnered oncology therapies, including Jemperli and imsidolimab. The company’s next catalyst is the Jan 24, 2027 — Q3 2026 Earnings Release, which will test its ability to deliver consistent earnings guidance and progress on its royalty-generating partnerships.

  • ANAB operates in a high-margin, asset-light model, leveraging its IP and partnerships to generate recurring revenue.
  • The company has a history of meeting estimates but lacks near-term catalysts to drive upside.
  • Its financials remain heavily leveraged, with a net loss of $115.03M in Q1 2026 and a free cash flow deficit of $166.07M over the last 12 months.

The Read

2% after Q1 2026 earnings met expectations without upside surprise.

The schedule

No upcoming catalysts on the current packet.

Past

  • Mon3Aug

    Actual outcome: Bull · $54.99 at outcome

    AnaptysBio reported Q2 2026 EPS of -$1.84, meeting consensus estimates exactly. The stock exceeded the bull target as investors reacted positively to the company's successful transition into a focused royalty management company post-spin, which eliminated prior R&D burn and established a 95% targeted EBIT margin with over $140 million in net cash. Optimism surrounding escalating Jemperli royalties from GSK further drove the bullish price action.

    First earnings print following recent spin-off activities, requiring updated full-year forward guidance and cash runway estimates.

  • Tue12May

    Actual outcome: Bear · $63.21 at outcome

    AnaptysBio reported an EPS actual of -1.84, matching the estimate, but the stock fell 3.5% due to mixed guidance and uncertainty around partnership progress. The earnings beat was overshadowed by concerns over the company's ability to meet long-term revenue targets, leading to a bearish price reaction.

  • Tue3Mar

    Actual outcome: Bear · $39.80 at outcome

    AnaptysBio reported Q4 2025 EPS of $1.79, exactly meeting consensus estimates, alongside updates on the GSK Jemperli milestone accrual. While the in-line earnings and milestone visibility drove a 13% relief rally, the stock's closing price of $39.80 failed to reclaim the $44.00 bear floor, resulting in a bear classification.